Biomarker modeling of Alzheimer’s disease using PET-based Braak staging Gold-standard diagnosis of Alzheimer’s disease (AD) relies on histopathological staging systems
Rates of regional tau accumulation in ageing and across the Alzheimer’s disease continuum: An AIBL 18F-MK6240 PET study Background Tau PET imaging enables prospective longitudinal observation of the rate and location of tau accumulation in Alzheimer’s disease (AD)
Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer’s disease The clinical and pathophysiological correlates of locus coeruleus (LC) degeneration in Alzheimer’s disease (AD) could be clarified using a method to index LC integrity in vivo, neuromelanin-sensitive MRI (NM-MRI)
Tau Imaging with 18F-MK6240 across the Alzheimer’s Disease spectrum Tau deposition plays a critical role over cognition and neurodegeneration in Alzheimer’s disease (AD)
Comparing tau status determined via plasma pTau181, pTau231 and [ 18 F]MK6240 tau-PET The threshold for positivity was 15.085 pg/mL for plasma pTau181 and 17.652 pg/mL for plasma pTau231
Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages Tracking longitudinal tau tangles accumulation across the Alzheimer’s disease continuum is crucial to better understand the natural history of tau pathology and for clinical trials
Direct Comparison of the Tau PET Tracers 18 F-Flortaucipir and 18 F-MK-6240 in Human Subjects Tau PET tracers exhibit varying levels of specific signal and distinct off-target binding patterns that are more diverse than amyloid PET tracers
Deep learning improves utility of tau PET in the study of Alzheimer’s disease Positron emission tomography (PET) imaging targeting neurofibrillary tau tangles is increasingly used in the study of Alzheimer’s disease (AD), but its utility may be limited by conventional quantitative or qualitative evaluation techniques in earlier disease states
Collaborators Login